Tommy Thompson, the deep-sea engineer who discovered the SS Central America wreck, was released on March 4, 2026, after over a decade in federal prison for civil contempt. He refused to disclose the location of 500 gold coins valued at approximately $2.5 million. Questions about the coins' whereabouts and investor compensation remain unresolved.

Finnish universities are exploring wireless power transmission through various methods, but claims of a significant breakthrough are exaggerated. The most notable experiment, involving ultrasonic spark guidance, does not enable usable power transfer. Aalto University's wireless charging shows promise, yet overall, the research is still nascent and limited to niche applications.

For the last however long, the word "AI" has been a four letter word in recording studios all over the globe. We’ve all seen...

Japanese researchers initiated Phase I human trials of a tooth-regrowing drug, TRG-035, at Kyoto University Hospital in October 2024, targeting USAG-1 protein inhibition. With 30 participants, the trials aim for commercial readiness by 2030. While promising, experts caution that significant challenges remain before widespread availability.

KEY POINTS: • The United States officially withdrew from the World Health Organization on January 22, 2026, one year after President Trump signed Executive Order...

Finnish universities are exploring wireless power transmission through various methods, but claims of a significant breakthrough are exaggerated. The most notable experiment, involving ultrasonic spark guidance, does not enable usable power transfer. Aalto University's wireless charging shows promise, yet overall, the research is still nascent and limited to niche applications.

For the last however long, the word "AI" has been a four letter word in recording studios all over the globe. We’ve all seen...

Japanese researchers initiated Phase I human trials of a tooth-regrowing drug, TRG-035, at Kyoto University Hospital in October 2024, targeting USAG-1 protein inhibition. With 30 participants, the trials aim for commercial readiness by 2030. While promising, experts caution that significant challenges remain before widespread availability.